Current clinical studies using liquid biopsy in glioblastomas
Year | Study | Tumor | Name/Method | Outcome measures |
---|---|---|---|---|
2020–2024 | NCT04201873 [72]Interventional phase I | 40 Recurrent GBM | RNA-seq and nanoString IO360 | Other outcome/measures: gene expression signature from peripheral blood before/after treatment |
2020–2025 | NCT04274283 [73]Observational | 1,000 Glioma II–IV | Tessa Jowell BRAIN MATRIX, whole genome and epigenomic classification | Matching tumor and blood, but not CSF, for targetable mutations |
2021–2024 | NCT04931732 [74]CircTeloDIAGObservational | 150 MRI suspected: glioma II–IV, incl. GBM | CicTeloDIAG3 oncogenic pathways:IDHTERTATRX | Validate liquid biopsy for glioma II–IV; blood ctDNA (also from CTCs) for diagnosis and monitoring of relapse |
2021–2025 | NCT05099068 [75]Interventional | 500 Advanced/metastatic tumors, GBM, CLL | PLANET sequential liquid biopsy, WES, RNA-seq | Monitoring changes in the genetic profile of GBM after chemotherapy |
2022 | Pagès et al. [76] | 258 CNS tumors, incl. HGG (no adult GMB) | ULP-WGS | ctDNA detection: CSF > blood, not in urine. Liquid biopsy is useful for high-grade tumors |
2022 | NCT04539431 [77]Observational | 220 Glioma | SensiScreen glioma | Validation of cheaper, more sensitive PCR-platform for liquid biopsy (blood and CSF), comparison with tissue |
2022–2023 | NCT05383872 [78]Diagnostic | 57 GBM | Microbubble resonator (Exablate Model 4000) | BBBD or liquid biopsy expected to increase cfDNA |
2022–2024 | NCT05281731 [87]Interventional | 20 GBM | Sonobiopsy device testing, blood ctDNA, deep sequencing | Matching mutations post-sonobiopsy and tumor tissue |
2022 | NCT05133154 [79]Exploratory | 50 Participants, DLGG (30 low-grade, 10 high-grade glioma, 10 controls) | Liquid biopsy in low-grade glioma, CTC, TEP | Search for CTCs (> 0), TEP in blood, evaluation of blood-based biomarkers (IDH, 1p19q, ATRX) for diagnosis and monitoring |
2022–2023 | NCT05536024 [80]Observational | 500 Glioma | Liquid biopsy, deep learning MRI | Prediction of glioma grading and molecular subtype |
IO360: Immuno-Oncology 360°; HGG: high-grade glioma; ULP-WGS: ultra-low-pass whole-genome sequencing
We gratefully acknowledge the introduction into the field of brain tumor research by Otmar D. Wiestler and the late Paul Kleihues, as well as discussions with Irving L. Weissman and Eugene C. Butcher on immune and tumor cell migration and metastasis, and Catherine Alix-Panabières on liquid biopsy.
RHE: Conceptualization, Investigation, Writing—original draft, Writing—review & editing. MS: Conceptualization, Investigation, Writing—review & editing. Both of the authors read and approved the submitted version.
The authors declare that they have no conflicts of interest.
Not applicable.
Not applicable.
Not applicable.
Not applicable.
Not applicable.
© The Author(s) 2023.